The utility of body FDG PET in staging primary central nervous system lymphoma
Open Access
- 1 April 2008
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 10 (2), 223-228
- https://doi.org/10.1215/15228517-2007-061
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- Molecular Imaging of Proliferation in Malignant LymphomaCancer Research, 2006
- Detection of Subclinical Systemic Disease in Primary CNS Lymphoma by Polymerase Chain Reaction of the Rearranged Immunoglobulin Heavy-Chain GenesJournal of Clinical Oncology, 2006
- Positron-Emission Tomography and Assessment of Cancer TherapyNew England Journal of Medicine, 2006
- Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?Nuclear Medicine Communications, 2006
- Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS LymphomaJournal of Clinical Oncology, 2005
- Role of Positron Emission Tomography in LymphomaJournal of Clinical Oncology, 2005
- Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2005
- Occult systemic Non-Hodgkin's Lymphoma (NHL) in patients initially diagnosed as Primary Central Nervous System Lymphoma (PCNSL): How much staging is enough?Journal of Neuro-Oncology, 1995
- Prognostic factors in the diagnosis and treatment of primary central nervous system lymphomaCancer, 1989